Background: Bisphosphonates have an established role in the treatment of bone metastases
from a variety of solid tumours. The objective response to anti-resorptive treatment cannot be …

BACKGROUND. For patients with bone metastases, high N‐telopeptide of type I collagen
(NTX) levels correlate with increased risks of skeletal‐related events and death. However …

PURPOSE: The objective assessment of bone metastases is currently based on serial
changes in skeletal survey. We performed a prospective study to determine whether a …

Pyridinoline (PYD), deoxypyridinoline (DPD), and N-telopeptide (NTX) are markers of bone
resorption. In cancer patients with bone metastases, NTX is more often elevated than either …

Bone metastases frequently occur in patients with advanced solid tumors, particularly breast
and prostate cancers, and nearly all patients with multiple myeloma have some degree of …

Purpose Three large, randomized trials of patients with bone metastases recently
demonstrated that zoledronic acid reduces the risk of skeletal-related events. These trials …

BACKGROUND Bone metastases are a frequent complication of cancer disease. The
evaluation of metastatic bone disease is crucial for the primary cancer staging because it will …

Bisphosphonate therapy for the treatment of skeletal complications from osteolytic
metastases has become standard care in patients with cancer who have metastatic bone …

Metastatic bone disease is a frequent complication of breast and other cancers, resulting in
skeletal complications that are a significant cause of morbidity and mortality. Bone …

The molecular triad, which includes the receptor activator of nuclear factor kappa-B ligand
(RANKL), its receptor RANK, and the endogenous soluble RANKL decoy receptor …